Upstream Bio Inc (UPB) is not a strong buy at this time for a beginner investor with a long-term strategy. While the RSI indicates the stock is oversold, the overall technical indicators are bearish, and there are no significant positive catalysts or trading signals to suggest immediate upside potential. The financial performance shows improvement in losses but remains negative overall, and there is no recent news or analyst sentiment to support a buy decision.

Technical Analysis

The technical indicators for UPB are bearish. The MACD histogram is negative and contracting, the RSI indicates an oversold condition at 12.678, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 7.664), but the pivot point is significantly higher at 10.399, indicating limited upward momentum in the short term.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

The RSI indicates the stock is oversold, which could attract buyers. The company's financials show YoY improvement in revenue, net income, and EPS, suggesting progress.

Neutral/Negative Catalysts

The overall technical trend is bearish, with negative MACD and bearish moving averages. There is no recent news or significant hedge fund or insider activity to support a positive sentiment. The stock's historical volatility is high (218.79), which may deter long-term investors.

Financial Performance

In Q3 2025, revenue increased by 12.52% YoY to $683,000. Net income improved by 60.45% YoY but remains negative at -$33.75M. EPS improved by 53.66% YoY to -0.63. Gross margin remains at 100%. While there is improvement, the company is still unprofitable.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for UPB.

8 Analyst Rating

Wall Street analysts forecast UPB stock price to rise

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 7.700

Low

Averages

52.25

High

Current: 7.700

Low

Averages

52.25

High

Evercore ISI

Cory Kasimov

Outperform

initiated

$40

AI Analysis

2025-11-18

Reason

Evercore ISI

Cory Kasimov

Price Target

$40

AI Analysis

2025-11-18

initiated

Outperform

Reason

Evercore ISI analyst Cory Kasimov initiated coverage of Upstream Bio with an Outperform rating and $40 price target. The firm says the company's sole program verekitug is going after multi-billion dollar indications. Verekitug has a validated mechanism of action, offers a more convenient dosing schedule, and could potentially enable superior efficacy over current thymic stromal lymphopoietin targeting agents, the analyst tells investors in a research note. Evercore believes Upstream's Phase 2 asthma readout in Q1 of 2026 "could be a meaningful upside catalyst."

Truist

Buy

initiated

$47

2025-10-14

Reason

Truist

Price Target

$47

2025-10-14

initiated

Buy

Reason

Truist initiated coverage of Upstream Bio with a Buy rating and $47 price target. Verekitug offers similarly robust efficacy as other TSLP-receptor inhibitors, but with a much improved dosing schedule via targeting the receptor, the analyst tells investors. Given the size of the market and verekitug's value proposition, the firm thinks it could "easily become a mega-blockbuster drug," the analyst added.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for UPB

Unlock Now

UPB Should I Buy

UPB Should I Buy

Should You Buy Upstream Bio Inc (UPB) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch